Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biovica International : DiviTumŪTKa Monitoring Capabilities Confirmed in SWOG Study

11/17/2020 | 09:35am EST

Biovica, active in cancer diagnostics, today announced that new DiviTum®TKa results from a large SWOG Cancer Research Network study further strengthen DiviTum®TKa’s monitoring capabilities within metastatic breast cancer. The study, known as S0226, showed impressive data on progression free survival and overall survival. Furthermore, results support that DiviTum®TKa can predict benefit from metastatic breast cancer therapy. The new results will be presented at the world’s leading breast cancer conference, the San Antonio Breast Cancer Symposium, in December.

“We appreciate our collaboration with SWOG and are glad to see the study presented at the world´s leading breast cancer conference. The results from this large data set are highly encouraging and significantly expand the evidence base for DiviTumTKa. The data supports the intended use of DiviTumTKa as submitted for FDA approval, but also introduces a new possible prediction capability. We look forward to providing DiviTum®TKa for the benefit of patients with metastatic breast cancer,” said Anders Rylander, CEO of Biovica.

In the study, DiviTum®TKa was used to analyze over 1700 samples from more than 400 patients from the start of treatment and at four different timepoints during care. Large differences were observed in median progression free survival (11 vs. 17 months) and overall survival (30 vs. 58 months) between patients with high vs. low DiviTum® TKa baseline values. These differences were maintained at each of the treatment serial monitoring timepoints.

The study also showed that for patients without prior endocrine treatment and high DiviTum® TKa values, overall survival was significantly longer for patients treated with combination endocrine treatment vs. monotherapy. This supports a predictive capacity of DiviTum®TKa when selecting therapy for metastatic breast cancer patients.

“Our study demonstrates that measuring TK activity provides important information when evaluating and selecting therapy for patients with metastatic breast cancer. The results from this large data set support previous findings that DiviTum®TKa provides accurate prognosis and monitoring of progression free survival and overall survival for these patients. We look forward to continue our collaboration with Biovica to improve the lives of women with metastatic breast cancer,” said Costanza Paoletti, M.D. principal investigator of the study.

The study is the largest study to evaluate DiviTumTKa for prognostic and serial monitoring of metastatic breast cancer. The study is the foundation of the DiviTum®TKa clinical validation submitted to the FDA on September 25, 2020.

New DiviTum®TKa results from the SWOG study will be presented at the San Antonio Breast Cancer Symposium, December 8-12, 2020.

SWOG Cancer Research Network
SWOG is part of the National Cancer Institute’s (NCI) National Clinical Trials Network and the NCI Community Oncology Research Program, and is part of the oldest and largest publicly-funded cancer research network in the United States. SWOG has nearly 12,000 members in 47 states and six foreign countries who design and conduct clinical trials to improve the lives of people with cancer. SWOG trials have led to the approval of 14 cancer drugs, changed more than 100 standards of cancer care, and saved more than 3 million years of human life. Learn more at swog.org.
This news release uses data that will be presented at the San Antonio Breast Cancer Symposium obtained from the S0226 study and does not necessarily reflect the opinions or views of SWOG or the NCI.

© Modular Finance, source Nordic Press Releases

01/18BIOVICA INTERNATIONAL : DiviTumŪTKa in early treatment resistance trial
01/16BIOVICA INTERNATIONAL : FDA resource reallocation continues to impact DiviTumŪTK..
01/12BIOVICA INTERNATIONAL : CEO and main shareholder lends shares for redemption of ..
2020BIOVICA INTERNATIONAL : Q2 Interim Report August-October 2020/2021
2020BIOVICA INTERNATIONAL : DiviTumŪTKa included in new UK breast cancer study
2020BIOVICA INTERNATIONAL : Multicenter study PYTHIA presents positive DiviTumŪTKa r..
2020BIOVICA INTERNATIONAL : CDK 4/6 dosing study supports DiviTumŪTKa as an early an..
2020BIOVICA INTERNATIONAL : announces initial results in clinical genomics study of ..
2020BIOVICA INTERNATIONAL : DiviTumŪTKa Monitoring Capabilities Confirmed in SWOG St..
2020BIOVICA INTERNATIONAL : FDA submission will proceed to substantive review
More news
Sales 2021 3,00 M 0,36 M 0,36 M
Net income 2021 -38,5 M -4,61 M -4,61 M
Net cash 2021 134 M 16,0 M 16,0 M
P/E ratio 2021 -31,2x
Yield 2021 -
Capitalization 1 230 M 148 M 147 M
EV / Sales 2021 365x
EV / Sales 2022 25,7x
Nbr of Employees 21
Free-Float 75,2%
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOVICA INTERNATIONAL AB (PUBL)
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 67,00 SEK
Last Close Price 43,50 SEK
Spread / Highest target 137%
Spread / Average Target 54,0%
Spread / Lowest Target -28,7%
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Mattias Bergqvist Director-Clinical Development
Sector and Competitors